急性心肌梗死后就诊延迟患者冠状动脉微血管阻塞的影响因素及临床结局研究

doi:10.12114/j.issn.1007-9572.2019.00.220

摘要/Abstract

摘要： 背景约1/3的ST段抬高型心肌梗死（STEMI）患者出现就诊延迟，晚期心肌挽救治疗的益处受冠状动脉微血管阻塞（MVO）严重程度的影响。目的探讨急性心肌梗死后就诊延迟患者发生MVO的影响因素及临床结局。方法选取2014—2017年海南省人民医院急诊重症监护室和心脏重症监护室收治的就诊延迟（症状出现到就诊时间>12 h）、行急诊经皮冠状动脉介入治疗（PCI）的STEMI患者78例。根据冠状动脉造影结果，以心肌梗死溶栓试验（TIMI）血流分级≤2级或最终TIMI血流分级为3级且心肌灌注呈色等级（MBG）<2级为发生MVO。进行临床结局和超声心动图检查随访，以评估主要不良心血管事件（MACE）和左心室重构的发生情况。结果就诊延迟患者的MVO发生率为50.0%（39/78）。多因素Logistic回归分析结果显示，年龄大、罪犯血管为左前降支（LAD）是MVO发生的危险因素，梗死前心绞痛是MVO发生的保护因素（P<0.05）。有MVO患者的MACE发生率、左心室重构比例高于无MVO患者（P<0.05）。Cox比例风险回归模型分析结果显示，MVO、罪犯血管为LAD是MACE发生的预测因子（P<0.05）。结论 STEMI后就诊延迟患者的MVO及与其有关的预后不良事件发生风险较高，年龄大、罪犯血管为LAD是其危险因素，梗死前心绞痛是其保护因素，应对存在高风险的患者实施适当的管理和后续策略。

关键词: 心肌梗死, 就诊延迟, 微血管阻塞, 治疗结果, 影响因素研究

Abstract: Background About 1/3 of patients with ST-segment elevation myocardial infarction（STEMI） have delayed visits.The benefits of late myocardial salvage therapy are affected by the severity of coronary microvascular occlusion（MVO）．Objective To investigate the clinical outcomes，and related factors of MVO in coronary microvascular obstruction in patients with delayed admission after acute myocardial infarction.Methods From 2014 to 2017，78 STEMI patients with delayed admission（time between symptom onset and hospital arrival is greater than 12 hours） who received emergency percutaneous coronary intervention（PCI） in EICU and CICU，Hainan General Hospital were enrolled.According to the results of coronary angiography，MVO is determined when the thrombolysis in myocardial infarction（TIMI） perfusion grade is less than 2 or the final TIMI grade is 3 and the myocardial blush grade（MBG） is less than 2.Clinical results and echocardiographic follow-up were performed to assess the occurrence of major adverse cardiovascular events（MACE） and left ventricular remodeling.Results The incidence of MVO in the participants was 50.0%（39/78）．Multivariate Logistic regression analysis showed that older age and having left anterior descending branch as the culprit vessel were risk factors for MVO，and pre-infarction angina pectoris was protective factor for MVO（P<0.05）．The incidence of MACE and left ventricular remodeling in patients with MVO were higher than those of patients without（P<0.05）．Cox proportional hazards regression model showed that MVO and LAD were the predictors of MACE（P<0.05）．Conclusion STEMI patients with delayed admission are relatively susceptible to MVO and related adverse outcome events.Older age and having LAD as the culprit vessel are associated with increased risks while pre-infarction angina pectoris is associated with decreased risk of MVO.Appropriate management and follow-up strategies should be implemented in this group of high-risk patients.

Key words: Myocardial infarction, Delayed treatment, Microvascular obstruction, Treatment outcome, Root cause analysis

吴多益,许和平,孙娟,等. 急性心肌梗死后就诊延迟患者冠状动脉微血管阻塞的影响因素及临床结局研究[J]. 中国全科医学, 2019, 22(13): 1592-1597. DOI: 10.12114/j.issn.1007-9572.2019.00.220.
WU Duoyi,XU Heping,SUN Juan, et al. Clinical Outcomes and Related Factors of Coronary Microvascular Obstruction in Patients with Delayed Admission after Acute Myocardial Infarction [J]. Chinese General Practice, 2019, 22(13): 1592-1597. DOI: 10.12114/j.issn.1007-9572.2019.00.220.

参考文献

［1］MALIK A O，JONES P G，CHAN P S，et al．Association of long-term exposure to particulate matter and ozone with health status and mortality in patients after myocardial infarction［J］．Circ Cardiovasc Qual Outcomes，2019，12（4）：e005598．DOI：10.1161/CIRCOUTCOMES.119.005598.
［2］SINGH N，RATHORE V，MAHAT R K，et al．Glycogen phosphorylase BB：a more sensitive and specific marker than other cardiac markers for early diagnosis of acute myocardial infarction［J］．Indian J Clin Biochem，2018，33（3）：356-360．DOI：10.1007/s12291-017-0685-y.
［3］TWERENBOLD R，NEUMANN J T，S?RENSEN N A，et al．Prospective validation of the 0/1-h algorithm for early diagnosis of myocardial infarction［J］．J Am Coll Cardiol，2018，72（6）：620-632．DOI：10.1016/j.jacc.2018.05.040.
［4］DE CARVALHO L P，TAN S H，OW G S，et al．Plasma ceramides as prognostic biomarkers and their arterial and myocardial tissue correlates in acute myocardial infarction［J］．JACC Basic Transl Sci，2018，3（2）：163-175．DOI：10.1016/j.jacbts.2017.12.005.
［5］ISHII M，KAIKITA K，SATO K，et al．Cardioprotective effects of LCZ696（sacubitril/valsartan） after experimental acute myocardial infarction［J］．JACC Basic Transl Sci，2017，2（6）：655-668．DOI：10.1016/j.jacbts.2017.08.001.
［6］ELGENDY I Y，JNEID H.Microvascular obstruction in ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention：another frontier to conquer？［J］．J Thorac Dis，2018，10（3）：1343-1346．DOI：10.21037/jtd.2018.03.58.
［7］FRACASSI F，NICCOLI G.Angiogenesis and microvascular obstruction：still a research topic or a new therapeutic target？［J］．Rev Esp Cardiol（Engl Ed），2018，71（6）：420-422．DOI：10.1016/j.rec.2017.09.015.
［8］王江友，苏晞.急性心肌梗死患者冠状动脉微血管功能障碍和阻塞机制的研究进展［J］．中华老年心脑血管病杂志，2016，18（9）：996-998．DOI：10.3969/j.issn.1009-0126.2016.09.026.
WANG J Y，SU X.Research progress of coronary microvascular dysfunction and occlusion mechanism in patients with acute myocardial infarction［J］．Chinese Journal of Geriatric Heart Brain and Vessel Diseases，2016，18（9）：996-998．DOI：10.3969/j.issn.1009-0126.2016.09.026.
［9］FEISTRITZER H J，REINSTADLER S J，KLUG G，et al．Multimarker approach for the prediction of microvascular obstruction after acute ST-segment elevation myocardial infarction：a prospective，observational study［J］．BMC Cardiovasc Disord，2016，16（1）：239．DOI：10.1186/s12872-016-0415-z.
［10］MELE D，LUISI G A，PESTELLI G，et al．Echocardiography in ST-elevation myocardial infarction［J］．G Ital Cardiol（Rome），2018，19（9）：479-487．DOI：10.1714/2951.29666.
［11］BRAVO BAPTISTA S，FAUSTINO M，BRIZIDA L，et al．Early peripheral endothelial dysfunction predicts myocardial infarct extension and microvascular obstruction in patients with ST-elevation myocardial infarction［J］．Rev Port Cardiol，2017，36（10）：731-742．DOI：10.1016/j.repc.2017.01.006.
［12］KLONER R A.The importance of no-reflow/microvascular obstruction in the STEMI patient［J］．Eur Heart J，2017，38（47）：3511-3513．DOI：10.1093/eurheartj/ehx288.
［13］HONG N，LEE Y H，TSUJITA K，et al．comparison of the effects of ezetimibe-statin combination therapy on major adverse cardiovascular events in patients with and without diabetes：a meta-analysis［J］．Endocrinol Metab（Seoul），2018，33（2）：219-227．DOI：10.3803/EnM.2018.33.2.219.
［14］YU F T H，CHEN X，STRAUB A C，et al．The role of nitric oxide during sonoreperfusion of microvascular obstruction［J］．Theranostics，2017，7（14）：3527-3538．DOI：10.7150/thno.19422.
［15］RíOS-NAVARRO C，HUESO L，MI?ANA G，et al．Coronary serum obtained after myocardial infarction induces angiogenesis and microvascular obstruction repair.Role of hypoxia-inducible factor-1A［J］．Rev Esp Cardiol（Engl Ed），2018，71（6）：440-449．DOI：10.7150/thno.19422.
［16］STAMBOUL K，ZELLER M，ROCHETTE L，et al．Relation between high levels of myeloperoxidase in the culprit artery and microvascular obstruction，infarct size and reverse remodeling in ST-elevation myocardial infarction［J］．PLoS One，2017，12（7）：e0179929．DOI：10.1371/journal.pone.0179929.
［17］STIERMAIER T，THIELE H，EITEL I.Coronary microvascular obstruction：key factor in the prognosis of ST-segment-elevation myocardial infarction［J］．Circ Cardiovasc Imaging，2017，10（6）：e006568．DOI：10.1161/CIRCIMAGING.117.006568.
［18］ZHANG L，MANDRY D，CHEN B，et al．Impact of microvascular obstruction on left ventricular local remodeling after reperfused myocardial infarction［J］．J Magn Reson Imaging，2018，47（2）：499-510．DOI：10.1002/jmri.25780.
［19］SOEDA T.The mechanism of microvascular obstruction in patients with acute ST-segment elevation myocardial infarction：new light from optical coherence tomography［J］．Coron Artery Dis，2017，28（3）：188-189．DOI：10.1097/MCA.
［20］GOYAL A，YU F T H，TENWALDE M G，et al．Inertial cavitation ultrasound with microbubbles improves reperfusion efficacy when combined with tissue plasminogen activator in an in vitro model of microvascular obstruction［J］．Ultrasound Med Biol，2017，43
（7）：1391-1400．DOI：10.1016/j.ultrasmedbio.2017.02.013.
［21］OBER C D，OBER M C，IANCU A C.Serial transthoracic coronary Doppler shows complete reversibility of microvascular obstruction pattern at one month after reperfused acute myocardial infarction［J］．Med Ultrason，2017，19（1）：45-50．DOI：10.11152/mu-941.
［22］AIHARA H，FUMIKURA Y，NISHINA H.Value of 3-dimensional speckle tracking echocardiography in the prediction of microvascular obstruction and left ventricular remodeling in patients with ST-elevation myocardial infarction［J］．Circ J，2017，81（3）：353-360．DOI：10.1253/circj.CJ-16-0944.
［23］BULLUCK H，ROSMINI S，ABDEL-GADIR A，et al．Impact of microvascular obstruction on semiautomated techniques for quantifying acute and chronic myocardial infarction by cardiovascular magnetic resonance［J］．Open Heart，2016，3（2）：e000535．DOI：10.1136/openhrt-2016-000535.
［24］DE WAHA S，PATEL M R，GRANGER C B，et al．Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction：an individual patient data pooled analysis from seven randomized trials［J］．Eur Heart J，2017，38（47）：3502-3510．DOI：10.1093/eurheartj/ehx414.
［25］RAHBARI-OSKOUI F F，CHAPMAN A B.Hypoxia-inducible factor 1α（HIF-1α），Angiopoietin-2（ANG-2） and endocan：novel biomarkers of disease progression involving polycystic kidney disease［J］．Am J Nephrol，2018，47（4）：228-230．DOI：10.1159/000488116.
［26］MA M，DIAO K Y，YANG Z G，et al．Clinical associations of microvascular obstruction and intramyocardial hemorrhage on cardiovascular magnetic resonance in patients with acute ST segment elevation myocardial infarction（STEMI）：an observational cohort study［J］．Medicine（Baltimore），2018，97（30）：e11617．DOI：10.1097/MD.0000000000011617.

[1]	贾高鹏, 陈秋雨. 老年急性ST段抬高型心肌梗死经皮冠状动脉介入治疗术后心绞痛复发风险预测模型构建和验证：基于CYP2C19相关基因检测[J]. 中国全科医学, 2025, 28(30): 3779-3786.
[2]	王汝朋, 南京, 胡奕然, 杨升华, 金泽宁. 三酰甘油-葡萄糖体质量指数对2型糖尿病合并急性心肌梗死行急诊经皮冠状动脉介入治疗术后患者慢血流/无复流的预测价值研究[J]. 中国全科医学, 2025, 28(24): 2985-2992.
[3]	王久格, 湛武逸, 何安霞. 急性心肌梗死经皮冠状动脉介入治疗术后早期微循环灌注对左心室功能的影响研究[J]. 中国全科医学, 2025, 28(23): 2878-2884.
[4]	马盼盼, 王思静, 游娜, 丁大法, 鲁一兵. Danuglipron与Orforglipron治疗2型糖尿病疗效及安全性的Meta分析[J]. 中国全科医学, 2025, 28(21): 2679-2685.
[5]	朱子一, 何贵新, 秦伟彬, 宋惠, 张利文, 唐伟智, 杨斐斐, 刘凌云, 欧阳彬. 线粒体自噬改善心肌梗死后心肌纤维化及其中医药干预的研究进展[J]. 中国全科医学, 2025, 28(18): 2294-2300.
[6]	景涛, 戴永梅, 罗健英, 罗维, 季烨林凡, 彭驰, 张翠军, 曹彦俊, 郑清, 黄玉, 沈鹤军. 中国高中生的体质指数、膳食知识掌握水平、静坐时长及影响因素研究[J]. 中国全科医学, 2025, 28(16): 2025-2032.
[7]	黄晓韩, 朱铁英, 彭楠, 高恒波, 田英平, 姚冬奇. 急性心肌梗死心脏骤停患者心肺复苏后重组人尿激酶原溶栓治疗效果研究[J]. 中国全科医学, 2025, 28(15): 1898-1902.
[8]	邓毅凡, 何胜虎, 张晶, 朱莉. 钠-葡萄糖共转运蛋白2抑制剂对急性心肌梗死患者经皮冠状动脉介入治疗术后主要不良心血管事件发生的影响：一项Meta分析[J]. 中国全科医学, 2025, 28(15): 1884-1890.
[9]	孙沁瑜, 邓毅凡, 何胜虎, 张晶. 中性粒细胞/淋巴细胞比值、单核细胞/高密度脂蛋白胆固醇比值及两者联合对急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术后造影剂肾病的预测价值研究[J]. 中国全科医学, 2025, 28(15): 1891-1897.
[10]	曹干, 邓毅凡, 何胜虎, 张晶. 乳酸脱氢酶与白蛋白比值与急性ST段抬高型心肌梗死急诊经皮冠状动脉介入治疗术后患者预后的相关性研究[J]. 中国全科医学, 2025, 28(15): 1878-1883.
[11]	朱胜杰, 刁华琼, 杭晓屹, 孙文军. 不同中成药注射液治疗后循环缺血性眩晕效果的网状Meta分析[J]. 中国全科医学, 2025, 28(14): 1795-1808.
[12]	刘彩萍, 张艳华, 汤剑平, 汪程鹏, 薛丰丰, 王慧娟, 李传威, 张广亚, 李华芳. 注射用利培酮微球（Ⅱ）在精神分裂症患者维持治疗中的疗效和安全性研究[J]. 中国全科医学, 2025, 28(13): 1622-1627.
[13]	张滢, 姜欣彤, 王萍玉. 基于健康生态学模型的中国女性老年人群抑郁症状影响因素研究[J]. 中国全科医学, 2025, 28(13): 1595-1600.
[14]	马娟, 马盛宗, 燕茹, 马学平, 贾绍斌. C反应蛋白/白蛋白比值对2型糖尿病合并急性心肌梗死患者远期不良心脑血管事件的预测价值研究[J]. 中国全科医学, 2025, 28(06): 705-712.
[15]	汪雁博, 苏利芳, 刘畅畅, 周庆, 田佳, 支伟, 傅阳, 谷新顺. 不同剂量替格瑞洛治疗ST段抬高型心肌梗死患者的有效性和安全性：基于倾向性评分匹配[J]. 中国全科医学, 2025, 28(03): 372-378.